Literature DB >> 23463747

Risk association of HbA1c variability with chronic kidney disease and cardiovascular disease in type 2 diabetes: prospective analysis of the Hong Kong Diabetes Registry.

Andrea O Y Luk1, Ronald C W Ma, Eric S H Lau, Xilin Yang, Winnie W Y Lau, Linda W L Yu, Francis C C Chow, Juliana C N Chan, Wing-Yee So.   

Abstract

BACKGROUND: In type 2 diabetes, tight glycaemic control lowers the risk of diabetic complications, but it remains uncertain whether variability of glycaemia influences outcomes. We examined the association of glycated haemoglobin (HbA1c ) variability with incident chronic kidney disease and cardiovascular disease in a prospective cohort of 8439 Chinese patients with type 2 diabetes recruited from 1994 to 2007.
METHODS: Intrapersonal mean and SD of serially measured HbA1c were calculated. Chronic kidney disease was defined as estimated glomerular filtration rate <60 ml/min per 1.73 m². Cardiovascular disease was defined as events of ischemic heart disease, heart failure, ischemic stroke or peripheral vascular disease.
RESULTS: Over a median follow-up period of 7.2 years, 19.7 and 10.0% of patients developed chronic kidney disease and cardiovascular disease, respectively. Patients who progressed to chronic kidney disease had higher mean HbA1c (7.8 ± 1.3% vs 7.4 ± 1.2%, p < 0.001) and SD (1.0 ± 0.8% vs 0.8 ± 0.6%, p < 0.001) than nonprogressors. Similarly, patients who developed cardiovascular disease had higher mean HbA1c (7.7 ± 1.3% vs 7.4 ± 1.2%, p < 0.001) and SD (1.4 ± 1.1% vs 1.1 ± 0.8%, p < 0.001) than patients who did not develop cardiovascular disease. By using multivariate-adjusted Cox regression analysis, adjusted SD was associated with incident chronic kidney disease and cardiovascular disease with corresponding hazard ratios of 1.16 (95% CI 1.11-1.22), p < 0.001) and 1.27 (95% CI 1.15-1.40, p < 0.001), independent of mean HbA1c and other confounding variables.
CONCLUSIONS: Long-term glycaemic variability expressed by SD of HbA1c predicted development of renal and cardiovascular complications.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Keywords:  HbA1c variability; cardiovascular disease; chronic kidney disease; type 2 diabetes

Mesh:

Substances:

Year:  2013        PMID: 23463747     DOI: 10.1002/dmrr.2404

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  44 in total

1.  Association of the average rate of change in HbA1c with severe adverse events: a longitudinal evaluation of audit data from the Bavarian Disease Management Program for patients with type 2 diabetes mellitus.

Authors:  Florian C Bonke; Ewan Donnachie; Antonius Schneider; Michael Mehring
Journal:  Diabetologia       Date:  2015-10-30       Impact factor: 10.122

2.  Identifying the independent effect of HbA1c variability on adverse health outcomes in patients with Type 2 diabetes.

Authors:  J C Prentice; S D Pizer; P R Conlin
Journal:  Diabet Med       Date:  2016-07-17       Impact factor: 4.359

3.  Haptoglobin genotype modulates the relationships of glycaemic control with cognitive function in elderly individuals with type 2 diabetes.

Authors:  Elizabeth Guerrero-Berroa; Ramit Ravona-Springer; Anthony Heymann; James Schmeidler; Andrew Levy; Derek Leroith; Michal S Beeri
Journal:  Diabetologia       Date:  2015-01-28       Impact factor: 10.122

Review 4.  The Prevalence of Diabetic Microvascular Complications in China and the USA.

Authors:  Yu Kuei Lin; Bixia Gao; Lili Liu; Lynn Ang; Kara Mizokami-Stout; Rodica Pop-Busui; Luxia Zhang
Journal:  Curr Diab Rep       Date:  2021-04-09       Impact factor: 4.810

5.  A long-term anti-inflammation markedly alleviated high-fat diet-induced obesity by repeated administrations of overexpressing IL10 human umbilical cord-derived mesenchymal stromal cells.

Authors:  Liudi Wang; Tianyun Gao; Yu Li; Yuanyuan Xie; Sheng Zeng; Chenxu Tai; Yirui Feng; Pingping Shen; Bin Wang
Journal:  Stem Cell Res Ther       Date:  2022-06-17       Impact factor: 8.079

6.  Correlation between serum cystatin C level and renal microvascular perfusion assessed by contrast-enhanced ultrasound in patients with diabetic kidney disease.

Authors:  Ping Zhao; Nan Li; Lin Lin; Qiuyang Li; Yiru Wang; Yukun Luo
Journal:  Ren Fail       Date:  2022-12       Impact factor: 3.222

7.  Glycemic Variation and Cardiovascular Risk in the Veterans Affairs Diabetes Trial.

Authors:  Jin J Zhou; Dawn C Schwenke; Gideon Bahn; Peter Reaven
Journal:  Diabetes Care       Date:  2018-08-06       Impact factor: 19.112

8.  Association of glycaemic variability evaluated by continuous glucose monitoring with diabetic peripheral neuropathy in type 2 diabetic patients.

Authors:  Yu-Ming Hu; Li-Hua Zhao; Xiu-Lin Zhang; Hong-Li Cai; Hai-Yan Huang; Feng Xu; Tong Chen; Xue-Qin Wang; Ai-Song Guo; Jian-An Li; Jian-Bin Su
Journal:  Endocrine       Date:  2018-02-06       Impact factor: 3.633

9.  Direct association of visit-to-visit HbA1c variation with annual decline in estimated glomerular filtration rate in patients with type 2 diabetes.

Authors:  Akiko Takenouchi; Ayaka Tsuboi; Mayu Terazawa-Watanabe; Miki Kurata; Keisuke Fukuo; Tsutomu Kazumi
Journal:  J Diabetes Metab Disord       Date:  2015-09-14

10.  Development and Validation of a Clinical Risk-Assessment Tool Predictive of All-Cause Mortality.

Authors:  Ghalib A Bello; Gerard G Dumancas; Chris Gennings
Journal:  Bioinform Biol Insights       Date:  2015-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.